Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Melanoma antigen family B10 (MAGEB10)
- Target
- MAGEB10
- Molecular classification
- Cancer/testis antigen, Melanoma antigen protein family (MAGE family), Non-enzymatic, intracellular protein
01
Overview
Melanoma antigen family B10 (MAGEB10) is a member of the MAGE cancer/testis antigen family, normally restricted to testicular tissue but abnormally activated in various tumors[2][5]. Its protein assists in cellular processes related to proliferation and differentiation, and members of the MAGE family are often implicated in oncogenesis, promoting tumorigenic pathways by reprogramming gene regulatory circuits, impacting apoptosis, and genomic stability[2][4][5]. MAGEB10 is of considerable interest for cancer immunotherapeutic strategies and as a biomarker, although therapeutic interventions remain investigational and may present safety challenges due to antigen expression in non-cancerous germline tissue[4].
- Other names
- MAGEB10Melanoma-associated antigen B10FLJ32965MAGE-B10 antigenMelanoma antigen family B, 10Melanoma antigen family B10MAGE family testis and tumor-specific protein
02
Mechanism of action
Cancer immunotherapy (T-cell recognition and immune-mediated clearance of MAGEB10-expressing tumor cells); Potential modulation of ubiquitin signaling, impacting cell cycle regulators (by analogy with other MAGE family proteins)
03
Biological functions
Cell proliferation regulationSpermatogenesisApoptosis modulationPossible roles in differentiation and genomic stability
04
Disease associations
Cancer (notably sarcoma and other tumors)Potential immune response targeting in tumor cells (immunotherapy)
05
Safety considerations
On-target toxicity (risk if antigen is expressed in normal germline tissues e.g., testis, raising concerns for infertility or autoimmune responses)Tumor antigen heterogeneity (variable expression among tumors limits uniform targeting efficacy)
06
Interacting drugs
No approved drugs directly target MAGEB10 at present; however, broader MAGE family antigens are under investigation as immunotherapeutic and vaccine targets
07
Biomarkers
Overexpression in tumor tissue (cancer/testis antigen profile)Promising as biomarker for patient selection or monitoring in cancer immunotherapy
Beyond the preview
Go deeper on Melanoma antigen family B10 (MAGEB10).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Melanoma antigen family B10 (MAGEB10).